Quick Facts

• Approved Use: Management of acute, uncomplicated urinary tract infections (UTIs) in women and adolescent girls.
• Additional Role: May be utilized to support the prevention of infection during a prostate biopsy procedure in men.

---

Fosfomicina EG is utilized in therapeutic approaches to address certain bacterial infections. The primary approved application for the oral formulation is the short-course management of acute, uncomplicated infections of the lower urinary tract, specifically in adult women and adolescent females.

This medication is primarily indicated for these conditions when they are caused by specific strains of bacteria that are determined to be responsive to its effects. A key benefit of its use is the ability to achieve high concentrations in the urine, which is relevant for affecting susceptible bacteria within the bladder.

Furthermore, the oral formulation has an established role in the prevention of bacterial infections related to transrectal prostate biopsy procedures in men. The prescribing decision is informed by an evaluation of potential risk factors and local susceptibility patterns of common pathogens.

Regulatory References

1. EMA therapeutic overview

Official Eligibility Status

Fosfomicina EG's population eligibility is strictly defined by regulatory authorities based on age, organ function, and specific medical conditions.

Eligibility Status	Applicable Population/Condition
Use Permitted	Adult Women and Female Adolescents (aged 12 years and older); Adult Men (for certain prophylactic uses).
Not Recommended	Children below 12 years of age (safety and efficacy are not established for this group).
Conditional Use	Pregnant or Breastfeeding women (use is restricted and only permitted if deemed clearly necessary).

The medicine is strictly contraindicated for several populations. These exclusions apply to patients with known hypersensitivity to fosfomycin or any excipients in the formulation. Use is also prohibited for individuals with severe renal insufficiency (creatinine clearance less than 10 mL/min) or those undergoing haemodialysis, as the drug relies primarily on renal excretion. Furthermore, due to excipient content, the medicine must not be used by patients with specific hereditary metabolic disorders, such as fructose intolerance.

Interactions with other medicines and products

Official regulatory information for Fosfomycin tromethamine details specific pharmacokinetic and pharmacodynamic interaction patterns that may affect drug exposure or co-administered medications.

---

Pharmacokinetic Interactions and Timing Constraints

Co-administration with Metoclopramide or other medicinal products that increase gastrointestinal motility results in a pharmacokinetic interaction officially described as lowering the serum concentrations and urinary excretion of Fosfomycin. The official profile notes that Cimetidine does not affect Fosfomycin pharmacokinetics when taken concurrently.

• Interaction with Food: Food intake delays the absorption of Fosfomycin and is documented to cause a slight decrease in peak plasma levels and urinary concentrations. To mitigate this effect, official timing rules recommend administration on an empty stomach or separated by at least 2 to 3 hours after meals.

---

Pharmacodynamic Interactions and Restrictions

• Oral Anticoagulants: The regulatory profile includes a pharmacodynamic class effect caution, noting reports of increased oral anticoagulant activity in patients receiving antibiotic therapy. This risk requires consideration when Fosfomycin is co-administered.
• Live Bacterial Vaccines: The antibacterial action of Fosfomycin may reduce the effectiveness of Live Bacterial Vaccines (such as oral typhoid vaccine), necessitating consideration of this restriction.

Targeting the First Step in Bacterial Cell Wall Construction

Fosfomicina EG's active ingredient, fosfomycin, is an epoxide antibiotic that must first gain entry into the bacterial cell by exploiting the GlpT and UhpT transporters (a 'Trojan horse' mechanism). Once inside, fosfomycin acts as an analog of phosphoenolpyruvate (PEP) and functions as an irreversible, covalent inhibitor of the essential bacterial enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA). This enzyme catalyzes the first committed step in the synthesis of peptidoglycan, the crucial polymer that forms the bacterial cell wall.

Inactivation of MurA completely halts the production of peptidoglycan precursors. Without these components, the bacterial cell wall cannot be assembled or repaired, causing a rapid and profound loss of structural integrity. The compromised cell is unable to withstand its own internal osmotic pressure, leading directly to cell lysis and death (bactericidal effect).

Fosfomicina EG is utilized through two distinct officially approved routes of administration: oral via granules dissolved in water and intravenous (IV) infusion via powder for solution. The oral formulation is primarily structured as a single 3 g dose of Fosfomycin for short-course therapy. To ensure proper administration, the oral granules must be fully dissolved in a glass of water immediately before consumption.

This single dose must be administered on an empty stomach, typically 2 - 3 hours before or after food, and is often recommended to be taken after emptying the bladder, preferably at bedtime. For multi-dose regimens (e.g., prophylaxis or IV), if a dose is missed, it should not be doubled up.

For systemic or complicated infections, the intravenous route is employed. The standard adult dosing involves a total daily dose ranging from 12 g to 24 g, which is administered as divided doses (e.g., every 6 to 12 hours). Individual doses must not exceed 8 g and must adhere to mandatory infusion time protocols (e.g., 8 g infused over 60 minutes). Critically, the IV regimen requires dose adjustment for patients with renal impairment, where the dose is reduced based on the measured level of kidney function. Dosing for pediatric IV use is determined based on body weight.

Research evidence / Overview of studies for Fosfomicina EG

1. Evidence for use in Acute, Uncomplicated Urinary Tract Infections (UTIs)

The primary research for Fosfomicina EG was studied for its role in acute, uncomplicated infections of the lower urinary tract, a condition often characterized by symptoms that may vary in intensity. Researchers have primarily used Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews to study this use. These study designs typically compare a single dose of Fosfomicina EG against multi-day courses of other antibiotics.

Studies were conducted during periods of increased symptom activity in the observed populations, which were mainly non-pregnant adult women and adolescent girls. The main goals of this research were to measure both changes related to symptoms (Clinical Resolution) and bacterial status (Microbiological Resolution). Regulatory reviews of this evidence have described measurements of both symptom status and bacterial status, with some findings described patterns related to the measured short-term microbiological resolution when contrasted with specific longer-course comparators.

2. Evidence for use in Prevention of Infection During Prostate Biopsy

Fosfomicina EG was studied for a distinct purpose in men: the prevention of infectious complications following Transrectal Ultrasound-Guided Prostate Biopsy (TRUSPB). Research examined short-term changes in infection markers and was evaluated in a mix of Randomized Controlled Trials and Comparative Studies to explore its application as an infection prophylactic.

Studies monitored the post-procedure incidence of infection markers and related events, such as fever, UTI, or sepsis, within a defined short-term interval. Data show patterns related to its use as an alternative agent, but some comparative findings were mixed regarding the measured incidence of infectious complications.

3. Research Gaps and Unanswered Questions

The body of research, which was studied for authorized uses, also highlights areas where additional research is needed. Long-term effects and the durability of response are not fully established; follow-up durations were limited in many key studies, meaning the data provide limited information for long-term outcomes or how often infection markers may recur months or years later. Data for certain groups, such as men with uncomplicated UTIs or individuals with complicated urinary tract infections, remain insufficient, and the certainty of the evidence remains low in these specific, less-studied areas.

Common questions about Fosfomicina EG (FAQ)

Q: How quickly do people usually start to feel better after using this medicine?

Studies examining the primary authorized use of this medication measure the changes in a patient's symptoms, which is referred to as Clinical Resolution. Official information indicates that the specific time it takes for an individual to feel better can vary. The duration of symptom improvement depends on several individual factors.

Q: Is it normal to feel a mild stomach upset after using Fosfomicina EG?

Official product information documents gastrointestinal disturbances such as diarrhea, nausea, and dyspepsia as common adverse reactions. These effects are frequently reported by patients using the medication.

Q: Can Fosfomicina EG be used by people who have a history of kidney problems?

The medicine is strictly prohibited for individuals with severe renal insufficiency, which is defined by very low creatinine clearance (less than 10 mL/min). For patients with less severe kidney function impairment, its use is subject to special considerations and professional guidance, as dose adjustment may be necessary.

Q: How long does the active ingredient of Fosfomicina EG stay in the body?

Official pharmacokinetic information states that the mean elimination half-life is approximately 5.7 hours. This half-life is the time it takes for half of the drug to be eliminated from the body. Because of this, it takes several days for the active ingredient to be fully cleared from the body.

Q: Does Fosfomicina EG cause tiredness or fatigue?

According to official adverse reaction reports, instances of unusual tiredness, weakness, sleepiness, or unusual drowsiness have been included. If an individual experiences these effects, they are categorized as a known potential reaction.

Q: Does Fosfomicina EG have any known interactions with birth control pills?

Official regulatory warnings recognize that the use of antibiotics, as a drug class, can affect the natural bacteria in the gut (intestinal flora). This class effect may potentially carry a low risk of decreased effectiveness for oral hormonal contraceptives.

Q: Is Fosfomicina EG the same kind of medicine as other common antibiotics?

Fosfomicina EG is not chemically similar to many common antibiotics, such as penicillin (which belongs to the beta-lactam class). The active ingredient, fosfomycin, is classified as a distinct phosphonic acid derivative, giving it a unique structure and mechanism of action.

Q: Are there different forms of Fosfomicina EG available?

The medication is supplied in two main forms based on the route of administration. These include granules that are dissolved in water for oral use and a powder that is prepared for intravenous injection.

Q: Can taking Fosfomicina EG affect the results of any lab tests?

Regulatory guidance includes a statement that patients should inform their doctor or healthcare professional that they are using this medicine if they are about to have any blood tests. This is a common precaution for many medications.

Q: How is Fosfomicina EG different from Monuril or other brands?

The active ingredient in Fosfomicina EG is fosfomycin. The 'EG' in the name signifies that this is a specific manufacturer's preparation (Eurogenerics). Fosfomicina EG is considered a generic equivalent of other branded products containing fosfomycin, such as Monuril.

Q: Are there any specific foods or drinks that should be avoided while using this medicine?

Regulatory documents describe a possible interference when used concurrently with substances known as urinary alkalinisers. This is because these substances increase the alkalinity of the urine, which may interfere with the drug’s intended antibacterial action.

Q: Is there any research evidence about using Fosfomicina EG in older adults?

Regulatory guidance notes that use is generally not recommended in elderly patients due to a diminished rate of urinary excretion. If the medicine is used in older individuals, dose adjustment may be necessary, especially if age-related kidney function issues are present.

Q: What happens if someone accidentally uses more Fosfomicina EG than described in the directions?

Official safety information indicates that symptoms of an accidental overdose have included changes in hearing, balance problems (known as vestibular loss), and changes in taste perception. Overdose management is limited to providing symptomatic and supportive care.

Q: Is Fosfomicina EG an antibiotic or an antiviral medicine?

Fosfomicina EG is classified as an antibiotic, which is also known as an antibacterial agent. Its purpose is the elimination of bacterial infections, and it is not authorized for treating viral infections.

Q: Why is it important to mix the powder with water before using Fosfomicina EG?

The regulatory label requires the oral granules to be fully dissolved in a glass of water before consumption. Official instructions state this is required to ensure proper administration and optimal absorption of the active substance into the body. Official documents state that the granules must not be taken in their dry form.

Q: Can people who are lactose intolerant use Fosfomicina EG?

Official product documents are required to list all excipients (inactive ingredients). The medicine is strictly contraindicated for those with rare hereditary conditions like fructose intolerance due to its sucrose content. However, lactose is not typically listed among its excipients.

Q: Does the time of day matter when using Fosfomicina EG?

The time of day is a factor in optimizing the drug's effectiveness. Official instructions state that the oral dose should be administered on an empty stomach (2–3 hours after food) and suggest administration preferably at bedtime, after emptying the bladder.

Q: What is the purpose of the high dosage in a single treatment with this medicine?

The single, high-dose regimen is designed based on pharmacological principles. This approach is intended to achieve high concentrations of the active substance in the urine, and to maintain that concentration long enough to effectively eliminate the target bacteria.

Q: Can Fosfomicina EG cause a rash, and is that always serious?

Official regulatory documents list rash and pruritus (itching) as common side effects. However, severe allergic skin reactions like anaphylaxis (a serious, rapid reaction) or angioedema are rare, but are recognized as serious risks.

Q: How can I know if my symptoms are related to the side effects of Fosfomicina EG?

Patients are encouraged by regulatory safety bodies to maintain vigilance for any suspected adverse drug reactions. Regulatory safety information highlights the need for immediate medical attention if signs of a serious reaction are experienced, such as a severe rash, swelling of the face, or difficulty breathing.

Q: Is it safe to drive or operate machinery after using Fosfomicina EG?

Official product information carries a warning about the potential for dizziness. Regulatory documents contain explicit statements that if a person experiences dizziness, they must avoid driving, operating machinery, or participating in dangerous activities until the effect has passed.

Q: What are the ingredients in Fosfomicina EG besides the active substance?

The medication is composed of the active substance, fosfomycin trometamol. Official documents list the excipients (inactive ingredients), which are documented to include substances such as sucrose.

Q: Can Fosfomicina EG affect the natural bacteria in the gut?

Treatment with any antibacterial agent, including this one, can alter the normal balance of bacteria in the colon (gut flora). This alteration is associated with the risk of C. difficile-associated diarrhea, which can range from mild diarrhea to a more serious condition.

Q: Are there any specific warnings for people with diabetes using Fosfomicina EG?

Official documentation states that the oral granules contain sucrose as an excipient (an inactive ingredient that is a type of sugar). Official labeling includes this factual information as a specific consideration for patients who have diabetes.

Q: What is the general expectation for duration of action after the single dose?

The single dose is designed to maintain high concentrations of the active substance in the urine for an extended period. Pharmacological studies show that the concentration remains at therapeutic levels to eliminate target bacteria for up to 48 hours after administration.

Q: How common are serious allergic reactions to Fosfomicina EG?

Official regulatory safety reports highlight the potential for serious hypersensitivity reactions, such as anaphylaxis and angioedema. While these are considered risks, their occurrence is classified as infrequent or rare in reporting data.

Q: Can men use Fosfomicina EG for appropriate infections?

Official guidance states that the single-dose oral formulation is indicated for the treatment of acute uncomplicated lower urinary tract infections (UTIs) in both adult men and non-pregnant adult women. The medicine is also researched for use in men for certain prophylactic purposes.

Q: Are there any known interactions between Fosfomicina EG and vaccines?

Official regulatory documents warn that the antibacterial action of this medicine may reduce the effectiveness of live bacterial vaccines. An example is the oral typhoid vaccine, and this potential interaction is a factor that requires consideration.

Q: What is the official definition of the type of infection Fosfomicina EG is meant to treat?

The primary authorized use of this medicine is the treatment of acute uncomplicated lower urinary tract infections. This condition is officially referred to as acute cystitis, and it must be caused by organisms that are susceptible to the active substance.

How to Store and Dispose of Fosfomicina EG

The storage and disposal of Fosfomycin granules must adhere strictly to regulatory requirements to maintain product integrity and safety.

Storage Requirements

The medication must be stored at room temperature, typically below 25°C or 30°C, and kept in the original packet or sachet. It is required to protect the granules from moisture and direct light, and the product must not be refrigerated or frozen. For safety, the medicine must be kept out of the sight and reach of children.

Stability and Disposal

The oral solution, once prepared by mixing with water, should be used immediately and any remaining solution must be discarded if not administered within 24 hours. Unused or expired Fosfomycin must not be thrown away via wastewater or household waste and should be disposed of in accordance with local regulatory requirements.